WCN26-1853 2-y crovalimab paroxysmal nocturnal haemoglobinuria (PNH) data for fatigue, a relevant symptom in atypical haemolytic uraemic syndrome (aHUS) and PNH

Read full text Summarise with VIRAT
Authors: Ming‐Hui Zhao, Hannah Staunton, Jennifer Stefani, Patty Leon
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

aHUS is a rare, life-threatening, complement-mediated disease characterized by thrombotic microangiopathies. Established C5 inhibitors (C5is), eculizumab and ravulizumab, are effective but burdensome treatments, requiring intravenous infusions every 2 or 8 weeks, respectively. Crovalimab is a novel, low-volume, subcutaneous, self-administrable C5i dosed every 4 weeks. Crovalimab is being evaluated in aHUS in two ongoing global, Phase III, single-arm trials: COMMUTE-a (NCT04861259) and COMMUTE-p (NCT04958265).

Fields of Study & Subjects

Complement system in diseases Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
103946–103946
Publication date
25 March 2026
Language
EN